Head-to-head comparison
Semaglutide vs Tirzepatide
Physician-reviewed comparison
Semaglutide
Peer ReviewedFDA Approved
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Tirzepatide
Peer ReviewedFDA Approved
A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management.
Quick Comparison
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Category | glp1 | glp1 |
| Classification | GLP-1 Receptor Agonist | Dual GIP/GLP-1 Receptor Agonist |
| Evidence Rating | Peer Reviewed | Peer Reviewed |
| Regulatory Status | FDA Approved | FDA Approved |
| Delivery | Subcutaneous injection, Oral tablet | Subcutaneous injection |
| Complexity | 4 / 5 | 4 / 5 |
| Refrigeration | Required | Required |
Dosing Comparison
Semaglutide
Weight Loss (Wegovy)
0.25–2.4 mg · weekly
Type 2 Diabetes (Ozempic)
0.5–2 mg · weekly
Tirzepatide
Weight Loss (Zepbound)
2.5–15 mg · weekly
Type 2 Diabetes (Mounjaro)
2.5–15 mg · weekly
Can You Stack Them?
No known direct interaction between Semaglutide and Tirzepatide in our database. However, always consult your provider before combining compounds.
Medical Disclaimer
This comparison is for educational purposes only. Individual responses vary. Consult a qualified healthcare provider before using any compound.